ArticleKidney international reports2024
A Pilot Study on the Safety and Adequacy of a Novel Ecofriendly Hemodialysis Prescription-Green Nephrology.
Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Water conservation and circular water reuse in clinical haemodialysis facilities: a scoping review.International urology and nephrology · 2026Article
- Kidney health for all: caring for people, protecting the planet.Kidney medicine · 2026Article
- A website calculator to benchmark the carbon footprint of haemodialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Advancing green nephrology: a scoping review of sustainability interventions in kidney care.International urology and nephrology · 2026Article
- Kidney health for all: Caring for people, protecting the planet.Journal of family medicine and primary care · 2026Article
- Kidney health for all: caring for people, protecting the planet.Kidney international reports · 2026Article
- Kidney Health for all: Caring for People, Protecting the Planet.Canadian journal of kidney health and disease · 2026Article
- Economic and environmental impacts of a resource-saving committee in a Japanese hemodialysis clinic: a case study.Frontiers in health services · 2025Article
- How low can we go with the dialysate flow? A retrospective study on the safety and adequacy of a water-saving dialysis prescription.Clinical kidney journal · 2024Article
- Unused Hemodialysis Acid Concentrate is Dollars and Dialysate Down the Drain: An Opinion Piece.Canadian journal of kidney health and disease · 2024Article
- Kidney health for all: caring for people, protecting the planet.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemodialysis (HD) units require large quantities of water. To reduce water consumption without compromising the adequacy and safety of dialysis, we studied a novel HD prescription with high temperature and low flow dialysate. Methods: This was a single-center nonrandomized open-label cross-over pilot trial in patients with end-stage kidney disease on maintenance HD. Each participant was subjected to 3 different dialysis prescriptions for 1 month each as follows: (i) normal temperature with normal flow dialysate (NTNF prescription), (ii) high temperature with normal flow dialysate (HTNF prescription), and (iii) high temperature with low flow dialysate (HTLF prescription). The primary outcome, assessed at the end of each dialysis session, was the delivery of "adequate" dialysis, as defined by a single-pool Kt/V (spKt/V) ≥1.2. Outcomes were evaluated by comparing the NTNF and HTLF prescriptions. Results: A total of 863 sessions of HD were performed in 30 patients over 3 months, with 287 to 288 sessions in each of the 3 dialysis prescriptions. The primary outcome was not significantly different between the NTNF prescription (202 sessions [70.14%]) and the HTLF prescription (198 sessions [68.75%]) (odds ratio, 1.07; 95% confidence interval, 0.75 to 1.52; Conclusion: Increasing dialysate temperature while reducing dialysate flow rate (Q
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.